VIPR1

Across TCGA pan-cancer cohorts, VIPR1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VIPR1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VIPR1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated VIPR1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and HNSC are the cancer types where VIPR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.861	0.153	.024	3	view →
HNSC	DFS	Median	All	0.317	0.638	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

VIPR1–CCRCC (DFS)

Open the CCRCC breakdown →